23:50 , Aug 23, 2019 |  BC Extra  |  Company News

Management tracks: Erasca, Frequency, PerkinElmer, CytomX, Infinity and more

Erasca Inc. (San Diego, Calif.) promoted Chief Business Officer Gary Yeung to chief operating and financial officer and hired David Chacko to take over the CBO role. Chacko was a principal at investment firm Versant...
12:00 , Aug 22, 2019 |  BC Extra  |  Financial News

Eyeing new endpoints, Versant-backed Chinook reels in $65M series A for kidney therapies

Increased momentum in the kidney disease space, sparked in part by an evolution in FDA's thinking about approvable endpoints, encouraged a VC syndicate to back newly launched Chinook with $65 million in series A funding....
23:50 , Aug 21, 2019 |  BC Extra  |  Company News

Management tracks: VenatoRx builds out development team; plus Arbutus, Cadent and Arsenal Capital

Versant Ventures-backed VenatoRx Pharmaceuticals Inc. (Malvern. Pa.) hired Jennifer Ellis as SVP, quality. She was head of quality assurance at Tracon Pharmaceuticals Inc. (NASDAQ:TCON). The infectious disease company also hired Paul McGovern as VP, medical...
20:21 , Aug 9, 2019 |  BioCentury  |  Finance

Stem cells (re)generate rewards for Versant, Bayer

The combination of stem cells, gene therapy and regenerative medicine was not in vogue in 2016, but Versant and Bayer felt it had enough promise to make a bet on creating and funding BlueRock. Now...
11:00 , Aug 8, 2019 |  BC Extra  |  Company News

BlueRock becomes Bayer's cell therapy foundation

Three years after leading the $225 million series A round for stem cell company BlueRock, Bayer is doling out $240 million in cash up front to acquire the company outright. BlueRock Therapeutics L.P. will lay...
13:01 , Jul 1, 2019 |  BC Extra  |  Financial News

Versant, Bayer bet big on iPS cells to tackle price, efficacy of CAR therapies

Looking to tap allogeneic iPS cells to address the shortcomings of CAR cell therapies, Bayer and Versant Ventures launched Century Therapeutics on Monday with $250 million in funding. It’s the second time the partners have...
01:05 , Jun 28, 2019 |  BC Innovations  |  Translation in Brief

Banking on biomarkers for synthetic lethality

Repare thinks its biomarker-first approach could be a key differentiator for its synthetic lethal cancer drug programs. The company is collaborating with test developers ahead of time to recruit patients poised to benefit. Losing function...
03:07 , Jun 7, 2019 |  BC Innovations  |  Targets & Mechanisms

Following PARP, ATR axis next in line to expand synthetic lethal drug class

Promising ASCO readouts suggest targets in the ATR pathway are lining up behind PARP as the next drivers of “synthetic lethal” cancer killing. Biomarker and combination strategies presented at the American Society of Clinical Oncology...
00:29 , May 25, 2019 |  BC Extra  |  Financial News

New IPO filings include BridgeBio, Dermavant, Prevail, Atreca, Akero

In a week in which two biotechs went public and a third opted for a billion-dollar takeout instead of an IPO, five companies filed on Friday to list on NASDAQ in IPOs that could raise...
14:31 , May 8, 2019 |  BC Extra  |  Company News

Gilead’s Goldfinch deal signals renewed optimism in kidney therapies

In the latest sign of that the kidney is regaining attention for drug developers, Gilead has tapped Goldfinch's drug discovery tools to co-develop therapies for diabetic kidney disease and orphan kidney diseases. Goldfinch Biopharma Inc....